Nucleic Acid Therapeutics Contract Manufacturing Market (2026 to 2035)

 

Nucleic Acid Therapeutics Contract Manufacturing Market Summary:

The global Nucleic Acid Therapeutics Contract Manufacturing Market size was valued at USD 11425.8 million in 2025 and is projected to reach USD 50252.8 million by 2035, expanding at a CAGR of 15.97% from 2026 to 2035. The growth during the forecast period is driven by the rising demand for mRNA- and oligonucleotide-based therapies, increasing outsourcing to specialized CDMOs, expanding clinical pipelines for gene and RNA therapeutics, growing investments in advanced biomanufacturing infrastructure.

Nucleic Acid Therapeutics Contract Manufacturing Market Revenue Forecast, 2022–2035 (US$ Million)

Years	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035
Revenue (USD Mn)	7611.4	XX	XX	11425.8	XX	XX	XX	XX	XX	XX	XX	XX	XX	50252.8

Key Market Takeaways & Insights

• North America Nucleic Acid Therapeutics Contract Manufacturing Market held the largest share of 49.20% of the global market in 2025.
• The Nucleic Acid Therapeutics Contract Manufacturing industry in the Asia Pacific is expected to grow significantly over the forecast period.
• By Service Type, the Process Development & Optimization segment held the largest market share of 41.9% in 2025.
• By Workflow Stage, the Clinical Manufacturing (Phase I–III) segment held the largest market share in 2025.
• By Therapeutic Area, the infectious diseases segment is expected to witness the fastest growth during the forecast period.

Market Intelligence Overview (Historical, Current, Forecast):

• 2022 Nucleic Acid Therapeutics Contract Manufacturing Market Size: USD 7611.4 Million
• 2025 Nucleic Acid Therapeutics Contract Manufacturing Market Size: USD 11425.8 Million
• 2035 Nucleic Acid Therapeutics Contract Manufacturing Market Size: USD 50252.8 Million
• Nucleic Acid Therapeutics Contract Manufacturing Market CAGR (2026-2035): 15.97%

 

Nucleic Acid Therapeutics Contract Manufacturing Market Regional Forecast Analysis, 2026–2035 (US$ Million)

Region

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

North America

XX

XX

XX

5621.49

XX

XX

XX

XX

XX

XX

XX

XX

XX

22545.1

Europe

XX

XX

XX

3199.22

XX

XX

XX

XX

XX

XX

XX

XX

XX

13399.9

Asia Pacific

XX

XX

XX

2056.64

XX

XX

XX

XX

XX

XX

XX

XX

XX

11810.7

Middle East & Africa

XX

XX

XX

342.77

XX

XX

XX

XX

XX

XX

XX

XX

XX

1525.2

Latin America

XX

XX

XX

205.66

XX

XX

XX

XX

XX

XX

XX

XX

XX

971.8

Nucleic Acid Therapeutics Development Analysis:

• Genetic disease prevalence trends
• Rare disease patient assessment
• RNA-based therapy pipeline analysis
• Precision medicine development trends

Contract Manufacturing & Production Analysis:

• Oligonucleotide manufacturing capacity trends
• GMP production adoption assessment
• Outsourcing partnership analysis
• Scalable therapeutic production trends

Nucleic Acid Therapeutics Contract Manufacturing Market Outlook Analysis Conservative, Likely, Optimistic, (US$ Million), 2025–2035

	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035
Conservative	11425.8	XX	XX	XX	XX	XX	XX	XX	XX	XX	47033.9
Likely	11425.8	XX	XX	XX	XX	XX	XX	XX	XX	XX	50252.8
Optimistic	11425.8	XX	XX	XX	XX	XX	XX	XX	XX	XX	76234.1

Market Dynamics:
Market Drivers:

Rising Burden of Chronic and Genetic Diseases Driving Contract Manufacturing Demand

The increasing prevalence of chronic and genetic diseases is a key driver of the Nucleic Acid Therapeutics Contract Manufacturing Market. Growing incidence of conditions such as cancer, cardiovascular disorders, and inherited genetic diseases has accelerated the development of RNA- and DNA-based therapeutics, including siRNA, mRNA, and antisense oligonucleotides. As pharmaceutical and biotechnology companies expand their pipelines, they increasingly rely on contract manufacturing organizations (CMOs/CDMOs) for scalable GMP production, process optimization, and regulatory compliance. According to the World Health Organization (WHO), approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded globally in 2022, highlighting the urgent need for advanced nucleic acid therapies and the manufacturing capacity required to support them.

Increasing Outsourcing by Biopharmaceutical Companies

Growing outsourcing of manufacturing activities by biopharmaceutical companies is a key driver of the Nucleic Acid Therapeutics Contract Manufacturing Market. As developers focus on research, clinical development, and commercialization, they increasingly partner with contract manufacturers for process development, GMP production, analytical testing, and regulatory support. Outsourcing reduces capital investment, shortens production timelines, and provides access to specialized expertise and advanced manufacturing technologies. The expanding pipeline of RNA- and DNA-based therapeutics further strengthens demand for reliable CDMOs capable of delivering scalable, high-quality manufacturing services.

Market Restraint:

RNA Instability and Manufacturing Complexities Restraining Market Growth

The instability of RNA molecules and technical challenges associated with their synthesis are significant restraints on the Nucleic Acid Therapeutics Contract Manufacturing Market. RNA is highly susceptible to degradation by nucleases, requiring stringent handling, specialized manufacturing environments, and advanced stabilization technologies to maintain product quality. In addition, synthesis errors, purification challenges, and process variability can reduce manufacturing efficiency and increase production costs. These technical complexities complicate large-scale GMP manufacturing, extend development timelines, and create barriers for contract manufacturers seeking to deliver consistent, high-quality nucleic acid therapeutics, ultimately limiting market growth.

Limited Large-Scale Manufacturing Capacity

A shortage of specialized large-scale manufacturing capacity remains a major restraint for the Nucleic Acid Therapeutics Contract Manufacturing Market. Producing nucleic acid therapeutics requires sophisticated facilities, highly skilled personnel, and strict GMP compliance, which are not widely available. Increasing demand for mRNA, siRNA, and gene therapies has intensified competition for manufacturing slots, resulting in capacity constraints and longer production timelines. Building new facilities requires substantial capital investment and regulatory approvals, limiting the ability of contract manufacturers to rapidly expand operations and meet growing market demand.

Market Opportunities:

Advancements in CRISPR and mRNA Technologies Creating Market Opportunities

Rapid developments in CRISPR gene-editing technologies and mRNA therapeutics present a significant growth opportunity for the Nucleic Acid Therapeutics Contract Manufacturing Market. Innovations such as base editing, prime editing, and next-generation mRNA platforms are expanding the pipeline of nucleic acid-based therapies for genetic, infectious, and chronic diseases. As these complex therapies advance through preclinical and clinical development, pharmaceutical and biotechnology companies increasingly rely on contract manufacturers for specialized process development, GMP production, formulation, and analytical testing. This growing demand for scalable and technically advanced manufacturing capabilities is expected to drive substantial market expansion in the coming years.

Expansion of Personalized and Precision Medicine

The rapid growth of personalized and precision medicine offers a significant opportunity for the Nucleic Acid Therapeutics Contract Manufacturing Market. Advances in genomic profiling and molecular diagnostics are enabling the development of patient-specific RNA- and DNA-based therapies tailored to individual genetic characteristics. These customized treatments require flexible manufacturing processes, small-batch production, and specialized quality control, creating strong demand for experienced contract manufacturers. As healthcare increasingly shifts toward targeted therapies for rare diseases, cancer, and inherited disorders, CDMOs with advanced capabilities are well positioned to benefit from expanding commercial and clinical manufacturing needs.

Nucleic Acid Therapeutics Contract Manufacturing Market Share Analysis by Service Type, 2025 (%)

By Service Type	2025
Process Development & Optimization	42%
Analytical & Quality Control (QC) Services	32%
Drug Product (Formulation, Fill & Finish)	15%
Regulatory Support & Technology Transfer	7%
Packaging & Fill–Finish Services	4%

Nucleic Acid Therapeutics Contract Manufacturing Market Segmentations Analysis:

By Service Type, Process Development & Optimization Holds the Largest Share in the Nucleic Acid Therapeutics Contract Manufacturing Market

The process development and optimization segment dominated the application segment in 2025, accounting for 41.9%, due to its critical role in ensuring product quality, scalability, and regulatory compliance. These services enable a smooth transition from laboratory-scale synthesis to large-scale GMP manufacturing, lowering production costs and time to market. In addition, contract manufacturers are increasingly using advanced analytics, automation, and AI-driven process modeling to improve reproducibility and yield. Furthermore, continuous manufacturing techniques and real-time monitoring are being used to meet the increasing demand for nucleic acid-based therapies such as mRNA, siRNA, and oligonucleotides.

The analytical and quality control services segment is expected to grow the fastest during the forecast period. This growth is being driven by rising demand for NGS-based high-resolution characterization of oligonucleotides and mRNA impurities, as well as rising regulatory requirements for detailed comparability and biosimilarity studies in nucleic acid therapeutics to detect modified nucleotide integrity and lipid nanoparticle payload consistency across GMP batches.

By Therapeutic Area, Rare Genetic Disorders Hold the Largest Share in the Market

The Rare Genetic Disorders segment accounted for the largest market share in 2025, driven by the increasing prevalence of inherited diseases and growing demand for precision therapies. Nucleic acid therapeutics targeting conditions such as cystic fibrosis, hemophilia, and spinal muscular atrophy have boosted the need for GMP-grade plasmid DNA and viral vector manufacturing. Additionally, advances in gene editing and delivery platforms, including AAV and lentiviral vectors, continue to strengthen this segment’s growth.

The infectious diseases segment is expected to witness the fastest growth during the forecast period, fueled by rising demand for vaccines and antiviral therapies. Increasing development of mRNA, siRNA, and DNA-based treatments, along with improvements in lipid nanoparticle delivery, RNA stabilization, and contract manufacturing capabilities, is accelerating production and expanding the adoption of nucleic acid therapeutics.

By Workflow Stage, Clinical Manufacturing (Phase I–III) Dominate the Nucleic Acid Therapeutics Contract Manufacturing Market

The Clinical Manufacturing (Phase I–III) segment holds the largest share of the Nucleic Acid Therapeutics Contract Manufacturing Market due to the growing number of candidates advancing through clinical trials. Biopharmaceutical companies increasingly rely on contract manufacturers for GMP-compliant production, process development, analytical testing, and regulatory support during Phase I–III studies. The rising pipeline of mRNA, siRNA, ASO, and gene therapies further drives demand for specialized clinical manufacturing services, making this the dominant segment.

The Commercial-Scale Production segment is the fastest growing as more nucleic acid therapeutics receive regulatory approvals and enter global markets. Large-scale manufacturing requires robust production capacity, quality assurance, and efficient supply chain management, encouraging pharmaceutical companies to outsource to experienced contract manufacturers. Expanding commercialization of RNA-based medicines and gene therapies, along with increasing patient demand, is accelerating investment in high-volume GMP manufacturing facilities and driving rapid segment growth.

By Therapy / Modality Type, mRNA-based Therapeutics Hold the Largest Share in the Market

The mRNA-based Therapeutics segment held the largest market share in 2025, accounting for 45.1%, driven by its effectiveness in treating cancer, genetic, and infectious diseases, along with rising government support. For instance, in September 2025, the UK government invested USD 30 million in CPI’s RNA Biofoundry to accelerate RNA therapy development. Continued advances in mRNA technologies, lipid nanoparticle (LNP) delivery, and AI-enabled manufacturing further strengthen segment growth.

The gene therapy segment is the fastest growing, fueled by the increasing prevalence of genetic disorders and demand for targeted treatments. According to the WHO, genetic disorders affect 2%–5% of live births globally. Advancements in AAV and LNP delivery systems, expanding regulatory approvals, and enhanced GMP manufacturing capabilities are accelerating clinical development and commercial production.

By End-User, Pharmaceutical and Biotechnology Companies’ Dominate the Nucleic Acid Therapeutics Contract Manufacturing Market

In 2025, the Biopharmaceutical / Biotechnology Companies segment had the largest revenue share in the Nucleic Acid Therapeutics Contract Manufacturing industry. This expansion is being driven by increased internal development of mRNA and oligonucleotide drug pipelines that require outsourced CDMO support, rising adoption of platform-based drug discovery models that enable rapid nucleic acid candidate screening, and a strong emphasis on rare disease and oncology biologics programs that necessitate scalable GMP manufacturing partnerships for accelerated clinical translation.

The Academic & Research Institutes segment is expected to grow at a significant CAGR over the forecast period, owing to large-scale national genome sequencing programs that generate population-wide RNA and DNA reference libraries for precision medicine, rising publicly funded CRISPR and mRNA vaccine research initiatives targeting infectious and rare genetic diseases, and expanding translational research pipelines in universities.

Nucleic Acid Therapeutics Contract Manufacturing Market Regional Analysis and Forecast, 2022–2035 (US$ Million)

By Geography	2022	2025	2035
North America	XX	5621.49	22545.1
US	XX	5205.50	XX
Canada	XX	415.99	XX
Europe	XX	3199.22	13399.9
Germany	XX	655.84	XX
UK	XX	409.50	XX
France	XX	499.08	XX
Italy	XX	275.13	XX
Spain	XX	262.34	XX
Switzerland	XX	99.18	XX
Netherlands	XX	67.18	XX
Rest of Europe	XX	930.97	XX
Asia Pacific	XX	2056.64	11810.7
China	XX	861.73	XX
India	XX	156.30	XX
Japan	XX	324.95	XX
South Korea	XX	294.10	XX
Singapore	XX	74.04	XX
Australia	XX	106.95	XX
Thailand	XX	26.74	XX
Malaysia	XX	51.42	XX
Philippines	XX	41.13	XX
Indonesia	XX	32.91	XX
Rest of Asia Pacific	XX	86.38	XX
Middle East & Africa	XX	342.77	1525.2
Saudi Arabia	XX	112.43	XX
United Arab Emirates	XX	88.78	XX
South Africa	XX	51.76	XX
Egypt	XX	28.11	XX
Israel	XX	24.68	XX
Rest of MEA	XX	37.02	XX
Latin America	XX	205.66	971.8
Brazil	XX	67.66	XX
Mexico	XX	48.33	XX
Argentina	XX	21.80	XX
Chile	XX	17.69	XX
Colombia	XX	10.69	XX
Peru	XX	8.84	XX
Rest of LA	XX	30.64	XX

North America Nucleic Acid Therapeutics Contract Manufacturing Market Analysis:

North America Nucleic Acid Therapeutics Contract Manufacturing Market held the largest share of 49.20% of the global market in 2025 and was valued at approximately USD 5621.49 million. The regional market is primarily driven by the strong demand for GMP production capacity, and growing precision medicine initiatives.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 North America Nucleic Acid Therapeutics Contract Manufacturing Market Size: USD 5621.49 Million
• 2035 North America Nucleic Acid Therapeutics Contract Manufacturing Market Size: USD 22545.1 million
• North America Nucleic Acid Therapeutics Contract Manufacturing CAGR (2026-2033): 14.9%

Drivers

• Rising RNA-based drug development activities

• Growing outsourcing of nucleic acid manufacturing

• Expanding gene therapy clinical pipelines

Restraints

• High manufacturing setup costs

• Complex production workflows

• Stringent regulatory requirements

Opportunities

• Rising CDMO partnership agreements

• Increasing rare disease therapy programs

United State Nucleic Acid Therapeutics Contract Manufacturing Market Analysis:

The U.S. accounted for the dominant share within North America and represented approximately 14.7% of the regional market in 2025. The U.S. Nucleic Acid Therapeutics Contract Manufacturing Market was valued at nearly USD 5205.50 million, supported by rising investments in advanced biomanufacturing.

Drivers

• Growing demand for outsourced GMP services

• Increasing clinical trial activities

• Rising investments in advanced biomanufacturing

Restraints

• High operational expenditure requirements

• Regulatory compliance complexities

• Manufacturing capacity constraints

Opportunities

• Rising pharmaceutical outsourcing contracts

• Increasing AI-enabled process optimization

Canada Nucleic Acid Therapeutics Contract Manufacturing Market Analysis:

Canada represented approximately 16.2% of the North American market in 2025 and was valued at around USD 415.99 million. The market is witnessing steady growth due to growing precision healthcare initiatives.

Drivers

• Growing biotechnology research investments

• Expanding nucleic acid clinical programs

• Rising demand for contract manufacturing services

Restraints

• High technology acquisition costs

• Dependence on imported raw materials

• Workforce availability challenges

Opportunities

• Rising cross-border CDMO partnerships

• Increasing biologics manufacturing investments

Europe Nucleic Acid Therapeutics Contract Manufacturing Market Analysis:

Europe accounted for approximately 28.00% of the global Nucleic Acid Therapeutics Contract Manufacturing Market in 2025 and was valued at nearly USD 3199.22 million. The market benefits from growing demand for specialized manufacturing.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Europe Nucleic Acid Therapeutics Contract Manufacturing Market Size: USD 3199.22 Million
• 2035 Europe Nucleic Acid Therapeutics Contract Manufacturing Market Size: USD 13399.9 million
• Europe Nucleic Acid Therapeutics Contract Manufacturing CAGR (2026-2033): 15.4%

Drivers

• Rising pharmaceutical outsourcing trends

• Increasing biotechnology funding programs

• Growing demand for specialized manufacturing

Restraints

• High compliance and validation costs

• Limited production scalability in some regions

• Complex regulatory frameworks

Opportunities

• Expansion of RNA therapeutics production sites

• Growth in personalized medicine manufacturing

United Kingdom Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

The UK represented approximately 14.6% of the European market in 2025 and was valued at nearly USD 409.50 million. The market is supported by rising government support for advanced therapies.

Drivers

• Expanding RNA drug research programs

• Growing outsourcing demand from biotech firms

• Increasing clinical development activities

Restraints

• High facility expansion costs

• Regulatory documentation burden

• Workforce skill shortages

Opportunities

• Rising partnerships with biotech startups

• Increasing advanced therapy investments

Germany Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Germany accounted for approximately 16.2% of the European market in 2025 and was valued at around USD 655.84 million. The country remains a key European hub for rising demand for contract development services.

Drivers

• Strong pharmaceutical manufacturing sector

• Growing nucleic acid therapy pipelines

• Expanding GMP production capabilities

Restraints

• High labor and operational costs

• Strict regulatory compliance standards

• Complex technology transfer processes

Opportunities

• Growth in commercial-scale RNA production

• Rising strategic outsourcing agreements

France Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

The France accounts for approximately 15.6% of the European market in 2025 and is valued at nearly USD 499.08 million. The market is supported by increasing government healthcare investments.

Drivers

• Rising demand for GMP manufacturing services

• Increasing government healthcare investments

Restraints

• High production infrastructure costs

• Regulatory complexity for advanced therapies

• Limited manufacturing scale availability

Opportunities

• Rising personalized medicine demand

• Increasing advanced therapy investments

Italy Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Italy accounted for approximately 14.8% of the European market in 2025 and was valued at around USD 275.13 million. The country remains a key European hub for growing healthcare innovation funding.

Drivers

• Growing pharmaceutical outsourcing activities

• Expanding biotechnology sector development

• Increasing RNA therapy research programs

Restraints

• Limited large-scale production facilities

• High capital investment requirements

• Regulatory approval challenges

Opportunities

• Rising international outsourcing contracts

• Increasing technology transfer projects

Spain Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

The Spain represented approximately 14.5% of the European market in 2025 and was valued at nearly USD 262.34 million. The market is supported by growing advanced therapy programs.

Drivers

• Growing life science research activities

• Increasing nucleic acid drug development

• Rising outsourcing demand from innovators

Restraints

• High validation and compliance costs

• Dependence on imported technologies

• Workforce skill gaps

Opportunities

• Rising biologics manufacturing investments

• Increasing personalized therapy projects

Switzerland Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Switzerland accounted for approximately 15.5% of the European market in 2025 and was valued at around USD 99.18 million. The country remains a strong pharmaceutical innovation leadership

Drivers

• Strong pharmaceutical innovation leadership

• Expanding nucleic acid therapeutic pipelines

• Growing demand for premium CDMO services

Restraints

• Strict quality compliance requirements

• Capacity expansion constraints

Opportunities

• Rising strategic biotech partnerships

• Increasing precision medicine programs

Netherlands Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

The Netherlands represented approximately 15.2% of the European market in 2025 and was valued at nearly USD 67.18 million. The market is supported by increasing life science investments.

Drivers

• Rising contract manufacturing demand

• Growing clinical development activities

• Increasing life science investments

Restraints

• Regulatory compliance challenges

• Production scale limitations

• Dependence on specialized raw materials

Opportunities

• Rising pharmaceutical collaborations

• Increasing automated manufacturing adoption

Asia Pacific Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Asia-Pacific accounted for approximately 18.00% of the global market in 2025 valued at nearly USD 2056.64 million. Rising healthcare innovation investments is significantly contributing to regional growth.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Asia Pacific Nucleic Acid Therapeutics Contract Manufacturing Market Size: USD 2056.64 Million
• 2035 Asia Pacific Nucleic Acid Therapeutics Contract Manufacturing Market Size: USD 11810.7 Million
• Asia Pacific Nucleic Acid Therapeutics Contract Manufacturing CAGR (2026-2033): 19.1%

Drivers

• Rapid biotechnology industry expansion

• Growing RNA therapeutics development

• Increasing outsourcing from global sponsors

Restraints

• Limited advanced production expertise

• Quality standardization challenges

• Infrastructure gaps in emerging markets

Opportunities

• Growth in mRNA manufacturing capacity

• Rising foreign direct investments

China Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

China represented approximately 18.6% of the Asia-Pacific market in 2025 valued at around USD 861.73 million. The market is expanding rapidly due to the increasing pharmaceutical outsourcing demand.

Drivers

• Strong domestic biotech expansion

• Growing siRNA development programs

Restraints

• Regulatory review complexities

• Dependence on imported equipment

Opportunities

• Growth in export-focused CDMO services

• Rising international biotech collaborations

India Nucleic Acid Therapeutics Contract Manufacturing Market Analysis:

India accounted for approximately 21.0% of the Asia-Pacific market in 2025 valued at nearly USD 156.30 million. Growing biotechnology startup ecosystem is driving market expansion across the country.

Drivers

• Growing biotechnology startup ecosystem

• Rising clinical research activities

Restraints

• Limited large-scale RNA facilities

• Regulatory compliance challenges

Opportunities

• Growth in global outsourcing contracts

• Rising investments in advanced therapy production

Japan Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Japan represented approximately 17.6% of the Asia-Pacific market in 2025 valued at around USD 324.95 million. The market is characterized by increasing demand for specialized manufacturing.

Drivers

• Advanced biotechnology research infrastructure

• Growing RNA-based drug innovation

• Strong pharmaceutical industry presence

Restraints

• High operational costs

• Workforce aging challenges

• Limited facility expansion capacity

Opportunities

• Expansion of automated manufacturing systems

• Rising strategic CDMO partnerships

South Korea Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

South Korea represented approximately 18.2% of the Asia-Pacific market in 2025 and was valued at around USD 294.10 million. The market is expanding rapidly due to strong government biotech initiatives.

Drivers

• Growing CDMO sector development

• Increasing biopharma investments

• Rising technology innovation activities

Restraints

• Dependence on imported raw materials

• Regulatory compliance burden

• Skilled workforce shortages

Opportunities

• Growth in global contract manufacturing projects

• Rising advanced therapy collaborations

Singapore Nucleic Acid Therapeutics Contract Manufacturing Market Analysis:

Singapore accounted for approximately 19.4% of the Asia-Pacific market in 2025 valued at nearly USD 74.04 million. Increasing innovation funding support is driving market expansion across the country.

Drivers

• Strong biomedical research ecosystem

• Growing advanced therapy investments

• Strategic location for biopharma operations

Restraints

• High labor costs

• Space constraints for facility expansion

Opportunities

• Growth in regional CDMO leadership

• Expansion of RNA therapeutics production

Australia Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Australia represented approximately 18.4% of the Asia-Pacific market in 2025 and was valued at around USD 106.95 million. The market is characterized by growing biotechnology sector investments.

Drivers

• Strong clinical trial environment

• Growing biotechnology sector investments

• Expanding gene-based therapy research

Restraints

• Limited manufacturing scale

• High production costs

• Geographic supply chain challenges

Opportunities

• Growth in international outsourcing agreements

• Rising translational research partnerships

Thailand Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Thailand represented approximately 19.2% of the Asia-Pacific market in 2025 and was valued at around USD 26.74 million. The market is expanding rapidly due to the government support for life sciences.

Drivers

• Growing pharmaceutical manufacturing sector

• Increasing biotechnology investments

• Rising contract production demand

Restraints

• Limited technical expertise availability

• Regulatory framework evolution

• Infrastructure limitations

Opportunities

• Expansion of RNA production services

• Rising foreign investment projects

Malaysia Nucleic Acid Therapeutics Contract Manufacturing Market Analysis:

Malaysia accounted for approximately 18.9% of the Asia-Pacific market in 2025 and was valued at nearly USD 51.42 million. Increasing outsourcing opportunities is driving market expansion across the country.

Drivers

• Expanding biotechnology industry

• Growing healthcare R&D investments

• Increasing outsourcing opportunities

Restraints

• Skilled labor shortages

• Dependence on imported technologies

Opportunities

• Growth in therapeutic RNA manufacturing

• Rising global partnership agreements

Philippines Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Philippines represented approximately 19.3% of the Asia-Pacific market in 2025 and was valued at around USD 41.13 million. The market is characterized by improving research infrastructure.

Drivers

• Growing pharmaceutical sector development

• Increasing healthcare investments

• Expanding biotechnology awareness

Restraints

• Limited specialized manufacturing facilities

• Technical workforce gaps

• Regulatory development challenges

Opportunities

• Expansion of clinical supply manufacturing

• Rising biotechnology collaborations

Indonesia Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Indonesia represented approximately 19.7% of the Asia-Pacific market in 2025 and was valued at around USD 32.91 million. The market is expanding rapidly due to rising demand for advanced therapeutics.

Drivers

• Large pharmaceutical market expansion

• Increasing biotechnology investments

• Growing healthcare modernization initiatives

Restraints

• Infrastructure development gaps

• Limited expertise in nucleic acid production

Opportunities

• Growth in international outsourcing projects

• Rising technology transfer partnerships

Middle East & Africa Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Middle East & Africa accounted for approximately 3.00% of the global market in 2025 and was valued at nearly USD 342.77 Million. The market is gradually expanding due to growing research collaboration programs.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Middle East & Africa Nucleic Acid Therapeutics Contract Manufacturing Market Size: USD 342.77 Million
• 2035 Middle East & Africa Nucleic Acid Therapeutics Contract Manufacturing Market Size: USD 1525.2 Million
• Middle East & Africa Nucleic Acid Therapeutics Contract Manufacturing CAGR (2026-2033): 16.1%

Drivers

• Growing biotechnology sector investments

• Increasing demand for advanced therapeutics

• Rising healthcare infrastructure development

Restraints

• High capital investment requirements

• Shortage of skilled technical professionals

Opportunities

• Rising foreign direct investments

• Increasing technology transfer initiatives

Saudi Arabia Nucleic Acid Therapeutics Contract Manufacturing Market Analysis:

Saudi Arabia accounted for approximately 16.7% of the Asia-Pacific market in 2025 and was valued at nearly USD 112.43 million. Increasing demand for advanced therapies is driving market expansion across the country.

Drivers

• Growing pharmaceutical localization initiatives

• Rising healthcare innovation investments

Restraints

• Limited GMP manufacturing expertise

• Dependence on imported raw materials

• High facility establishment costs

Opportunities

• Rising international CDMO partnerships

• Increasing precision medicine investments

United Arab Emirates Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

United Arab Emirates represented approximately 17.0% of the Asia-Pacific market in 2025 and was valued at around USD 88.78 million. The market is characterized by increasing pharmaceutical production initiatives.

Drivers

• Strong healthcare investment climate

• Growing biotechnology ecosystem

• Rising advanced therapy demand

Restraints

• High operational expenses

• Dependence on imported expertise

Opportunities

• Rising biotech venture investments

• Increasing technology licensing agreements

South Africa Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

South Africa represented approximately 15.9% of the Asia-Pacific market in 2025 and was valued at around USD 51.76 million. The market is expanding rapidly due to government support for innovation initiatives.

Drivers

• Growing pharmaceutical manufacturing activities

• Increasing biotechnology research efforts

Restraints

• Limited production infrastructure

• Funding constraints for expansion projects

Opportunities

• Expansion of therapeutic manufacturing projects

• Rising international research collaborations

Egypt Nucleic Acid Therapeutics Contract Manufacturing Market Analysis:

Egypt accounted for approximately 16.3% of the Asia-Pacific market in 2025 and was valued at nearly USD 28.11 million. Government support for local manufacturing is driving market expansion across the country.

Drivers

• Expanding pharmaceutical production sector

• Growing healthcare investments

• Increasing biotechnology awareness

Restraints

• High technology acquisition costs

• Regulatory infrastructure gaps

Opportunities

• Rising foreign investment inflows

• Increasing technology transfer projects

Israel Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Israel represented approximately 16.4% of the Asia-Pacific market in 2025 and was valued at around USD 24.68 million. The market is characterized by strong academic-industry collaboration.

Drivers

• Strong biotechnology innovation ecosystem

• Growing RNA therapeutic research activities

Restraints

• High manufacturing costs

• Limited commercial-scale facilities

• Workforce competition for specialized talent

Opportunities

• Expansion of nucleic acid production technologies

• Rising global partnership agreements

Latin America Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Latin America accounted for approximately 1.80% of the global market in 2025 and was valued at around USD 205.66 Million. The market is witnessing gradual growth supported by growing advanced therapeutics awareness.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Latin America Nucleic Acid Therapeutics Contract Manufacturing Market Size: USD 205.66 Million
• 2035 Latin America Nucleic Acid Therapeutics Contract Manufacturing Market Size: USD 971.8 Million
• Latin America Nucleic Acid Therapeutics Contract Manufacturing CAGR (2026-2033): 16.8%

Drivers

• Growing pharmaceutical outsourcing demand

• Expanding biotechnology research activities

• Rising healthcare innovation investments

Restraints

• Regulatory inconsistencies across countries

• Dependence on imported technologies

Opportunities

• Rising technology transfer initiatives

• Increasing biopharma investments

Brazil Nucleic Acid Therapeutics Contract Manufacturing Market Analysis:

Brazil accounted for approximately 17.1% of the Asia-Pacific market in 2025 and was valued at nearly USD 67.66 million. Rising healthcare R&D investments is driving market expansion across the country.

Drivers

• Strong pharmaceutical manufacturing base

• Growing biotechnology innovation activities

Restraints

• High facility modernization costs

• Regulatory approval complexities

Opportunities

• Rising technology transfer projects

• Increasing biologics production investments

Mexico Nucleic Acid Therapeutics Contract Manufacturing Market Analysis:

Mexico accounted for approximately 16.3% of the Asia-Pacific market in 2025 and was valued at nearly USD 48.33 million. Competitive manufacturing costs is driving market expansion across the country.

Drivers

• Growing pharmaceutical production activities

• Increasing biotechnology sector investments

Restraints

• Regulatory compliance challenges

• Dependence on imported raw materials

Opportunities

• Expansion of GMP production facilities

• Rising foreign direct investments

Argentina Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Argentina represented approximately 17.3% of the Asia-Pacific market in 2025 and was valued at around USD 21.80 million. The market is characterized by increasing healthcare innovation funding.

Drivers

• Expanding life science research programs

• Growing demand for outsourced manufacturing

• Rising biotechnology development activities

Restraints

• Limited manufacturing scalability

• Import dependence for technologies

Opportunities

• Growth in international research partnerships

• Rising investment in biotech facilities

Chile Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Chile represented approximately 17.0% of the Asia-Pacific market in 2025 and was valued at around USD 17.69 million. The market is expanding rapidly due to growing biotechnology investment landscape.

Drivers

• Growing biotechnology investment landscape

• Increasing pharmaceutical innovation activities

• Rising demand for specialized manufacturing

Restraints

• High technology costs

• Limited skilled workforce availability

Opportunities

• Rising foreign partnership agreements

• Increasing research commercialization projects

Colombia Nucleic Acid Therapeutics Contract Manufacturing Market Analysis:

Colombia accounted for approximately 17.4% of the Asia-Pacific market in 2025 and was valued at nearly USD 10.69 million. Rising demand for outsourced production is driving the market growth

Drivers

• Growing biotechnology awareness

• Increasing healthcare investments

• Rising demand for outsourced production

Restraints

• Skilled labor shortages

• Import dependence for equipment

• Limited local supplier ecosystem

Opportunities

• Rising foreign investment opportunities

• Increasing technology transfer initiatives

Peru Nucleic Acid Therapeutics Contract Manufacturing Market Analysis

Peru represented approximately 16.7% of the Asia-Pacific market in 2025 and was valued at around USD 8.84 million. The market is characterized by growing pharmaceutical market development.

Drivers

• Increasing healthcare modernization initiatives

• Rising biotechnology sector interest

• Expanding research activities

Restraints

• Dependence on imported technologies

• High capital investment requirements

Opportunities

• Rising international collaboration agreements

• Increasing investment in advanced facilities

Nucleic Acid Therapeutics Contract Manufacturing Market Key Players: Mention the shareholding of major 5 players

Key Players	Market Share
Thermo Fisher Scientific Inc	17.8%
Danaher Corporation (Aldevron & IDT)	15.1%
WuXi AppTec Co., Ltd	12.6%
Merck KGaA (MilliporeSigma Life Science)	10.4%
Agilent Technologies, Inc	8.7%

Thermo Fisher Scientific Inc. – 17.8%

Thermo Fisher Scientific leads the Nucleic Acid Therapeutics Contract Manufacturing Market through its Patheon CDMO business, offering end-to-end manufacturing services for mRNA, oligonucleotide, plasmid DNA, and gene therapy products. Its extensive global manufacturing footprint, regulatory expertise, and strong relationships with biotechnology and pharmaceutical companies support its leading market position and continued expansion.

Danaher Corporation (Aldevron & IDT) – 15.1%

Danaher maintains a significant market share through Aldevron and Integrated DNA Technologies (IDT), which provide critical materials and manufacturing solutions for nucleic acid therapeutics. The company benefits from strong capabilities in plasmid DNA, mRNA, and CRISPR-related manufacturing. Continuous investments in production capacity and advanced technologies further strengthen its competitive position in the market.

WuXi AppTec Co., Ltd. – 12.6%

WuXi AppTec is a major contract manufacturing provider with comprehensive services spanning research, development, and commercial-scale production of nucleic acid therapeutics. Its integrated platform, large-scale manufacturing infrastructure, and expanding global customer base support strong market penetration. Growing demand for RNA-based therapies and gene-editing technologies continues to enhance the company's market presence.

Merck KGaA (MilliporeSigma Life Science) – 10.4%

Merck KGaA plays a key role in the market through its Life Science division, supplying manufacturing technologies, raw materials, and process development services for nucleic acid therapeutics. The company’s expertise in bioprocessing and pharmaceutical manufacturing supports broad adoption among therapy developers. Strategic investments in advanced therapeutic modalities further reinforce its market share.

Agilent Technologies, Inc. – 8.7%

Agilent Technologies holds a notable position in the Nucleic Acid Therapeutics Contract Manufacturing Market through its analytical, quality control, and manufacturing support capabilities. The company provides critical tools and services that enable efficient development and production of oligonucleotide and RNA-based therapeutics. Strong technological expertise and growing involvement in advanced therapeutics manufacturing support its market growth.

Nucleic Acid Therapeutics Contract Manufacturing Market Recent Developments

• In January 2025, Evonik collaborated with ST Pharm to expand RNA and nucleic acid therapeutic services, integrating LNP development and system solutions to streamline production, reduce complexity, and accelerate time-to-market for drug developers. This collaboration expands Evonik's CDMO offerings, allowing for the rapid growth and commercialization of nucleic acid therapeutics worldwide.
• In January, 2024, VGXI Inc., a CDMO that specializes in the development and production of nucleic acid biopharmaceuticals such as gene therapies, DNA vaccines, and RNA medicines, has formed a collaboration with Resilience. In this agreement, VGXI has served as a reliable plasmid DNA manufacturer, assisting Resilience's advanced therapy manufacturing efforts.
• In October 2025, Aspen Pharmacare settled a dispute related to an existing mRNA CDMO manufacturing contract for USD 26.4 million, confirming ongoing GMP production obligations under the agreement.
• In April 2025, Wacker Biotech, a contract development and manufacturing company and wholly owned subsidiary of Wacker Chemie AG, has announced a strategic collaboration with RNAV8 Bio. This collaboration seeks to accelerate the development and production of mRNA-based advanced therapies for the biopharmaceutical industry. The collaboration brings together Wacker Biotech's expertise in plasmid DNA and mRNA manufacturing, as well as lipid nanoparticle formulation, with RNAV8 Bio's innovative mRNA engineering platform. This collaborative effort aims to improve mRNA drug efficacy and provide comprehensive, integrated services in the evolving mRNA therapeutics CDMO landscape.

Nucleic Acid Therapeutics Contract Manufacturing Market Regulatory Landscape Analysis:

• FDA oversight for nucleic acid therapeutic production
• EMA focus on manufacturing quality standards
• PMDA support for advanced biologics manufacturing
• Expanding regulatory pathways for RNA-based therapies

Nucleic Acid Therapeutics Contract Manufacturing Market Patent & IP Landscape

• Growing oligonucleotide manufacturing patents
• Rising RNA therapeutics IP filings
• Expansion of delivery technology patents
• Innovation in large-scale production platforms

Nucleic Acid Therapeutics Contract Manufacturing Market Segmentations:

Our research framework strategically segments the large molecule bioanalytical testing services market by testing methodologies, modality landscape, end-user categories, and key regional markets

By Service Type

• Process Development & Optimization
  • cGMP Manufacturing
  • Drug Substance (API)
• Drug Product (Formulation, Fill & Finish)
• Analytical & Quality Control (QC) Services
• Regulatory Support & Technology Transfer
• Packaging & Fill–Finish Services

By Therapeutic Area

• Oncology
• Infectious Diseases
• Rare Genetic Disorders
• Cardiovascular & Metabolic Disorders
• Neurological Disorders

By Workflow Stage

• Preclinical Development
• Clinical Manufacturing (Phase I–III)
• Commercial-Scale Production

By Therapy / Modality Type

• mRNA-based Therapeutics
• DNA / Plasmid DNA Therapeutics
• siRNA (Small Interfering RNA)
• Antisense Oligonucleotides (ASOs)
• Gene Therapy Products
• Others

By End User

• Biopharmaceutical / Biotechnology Companies
• Pharmaceutical Companies
• Academic & Research Institutes

By Region & Country

North America

• U.S.
• Canada

Europe

• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Rest of EU

Asia Pacific

• China
• India
• Japan
• Australia
• South Korea
• Thailand
• Rest of APAC

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Rest of MEA

Latin America

• Brazil
• Argentina
• Mexico
• Rest of LA

Top Players

• Agilent Technologies, Inc.
• Bachem AG
• Ajinomoto Bio-Pharma Services
• BioSpring GmbH
• Exothera SA
• Helix Biotech
• LGC Group / Axolabs GmbH
• Thermo Fisher Scientific Inc. (Patheon)
• Danaher Corporation (Aldevron)
• WuXi AppTec Co., Ltd.
• Merck KGaA (MilliporeSigma Life Science)
• Curia Global, Inc. (formerly AMRI)
• KNC Laboratories Co., Ltd.
• Univercells / Univercells Technologies
• Integrated DNA Technologies (IDT, Danaher subsidiary)
• Evonik Industries AG (Health Care Business Line)
• Ology Bioservices (now part of National Resilience, Inc.)
• TriLink BioTechnologies (Maravai LifeSciences)
• AGC Biologics, Inc.
• Aurigene Pharmaceutical Services Ltd.
• PolyPeptide Group AG
• Eurofins Scientific SE (Eurofins Genomics Division)
• Kaneka Eurogentec S.A.
• Nitto Denko Avecia Inc.
• ST Pharm Co., Ltd.
• Others

Key Report Attributes	Details
Years Considered	2022 to 2035
Market Size 2025	USD 11425.8 Million
Market Size 2035	USD 50252.8 Million
Historical CAGR % (Growth rate)	XX from 2022 to 2025
Futuristic CAGR % (Growth rate)	15.97% from 2026 to 2035
Segments Covered	By Service Type By Therapeutic Area By Workflow Stage By Therapy / Modality Type By End User
Regions Covered	North America Europe Asia Pacific Middle East & Africa Latin America
Countries Covered	U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Switzerland, Netherlands, Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Singapore; Australia; Australia; Philippines; Indonesia; Brazil; Argentina; Indonesia; Chile; Colombia; Peru; South Africa; Egypt; Israel; Saudi Arabia; UAE; Kuwait
Competitive Landscape Overview	Agilent Technologies, Inc. Bachem AG Ajinomoto Bio-Pharma Services BioSpring GmbH Exothera SA Helix Biotech LGC Group / Axolabs GmbH Thermo Fisher Scientific Inc. (Patheon) Danaher Corporation (Aldevron) WuXi AppTec Co., Ltd. Merck KGaA (MilliporeSigma Life Science) Curia Global, Inc. (formerly AMRI) KNC Laboratories Co., Ltd. Univercells / Univercells Technologies Integrated DNA Technologies (IDT, Danaher subsidiary) Evonik Industries AG (Health Care Business Line) Ology Bioservices (now part of National Resilience, Inc.) TriLink BioTechnologies (Maravai LifeSciences) AGC Biologics, Inc. Aurigene Pharmaceutical Services Ltd. PolyPeptide Group AG Eurofins Scientific SE (Eurofins Genomics Division) Kaneka Eurogentec S.A. Nitto Denko Avecia Inc. ST Pharm Co., Ltd. Others
Flexible Report Customization	The study can be customized based on geography, segment analysis, company profiling, competitive benchmarking, and strategic insights.
Data Sources	Primary and secondary sources used (Company filings, trade associations, Journals, Annual report, Publications, Surveys, Investor Presentations, and much more.